To assess if enfuvirtide (ENF) increases antiviral activity of a highly active four-drug antiretroviral (ARV) regimen containing lopinavir/ritonavir, efavirenz, lamivudine and tenofovir in ARV-naive, HIV-infected patients.
Methods
Pilot study in ARV-naive, HIV-infected patients with viral load (VL) >10,000 copies/ml and no documented resistance to any of the study drugs. Patients were randomized to receive ENF (ENF Group) or not (Control Group) in combination with lopinavir/ritonavir, efavirenz, lamivudine and tenofovir as a backbone. The primary endpoint was to assess differences in the HIV-1 RNA decay rate during the first phase of viral decay. VL and treatment adherence were measured at baseline, every 6 h during the first 3 days, and once daily from day 3 to 6. Individual HIV-1 RNA decay rates were obtained using a non-linear least squares regression model.
Results
Eight subjects were included in each study group. Mean (sd) baseline VL was 4.98 (0.38) log10 copies/ml in the ENF Group and 5.10 (0.49) log10 copies/ml in the Control Group (P=0.607). Baseline CD4+ cell count was 463 (306) and 362 (225) cells/mm3 in the ENF and the Control Group, respectively (P=0.484). First phase HIV-1 RNA decay rate was 0.802 (0.127) d-1 in the ENF Group and 0.624 (0.182) d-1 in the Control Group (P=0.045). By day 6, VL was 3.55 (0.40) and 3.92 (0.36) log10 copies/ml in the ENF and the Control Group, respectively (P=0.079).
Conclusion
The addition of ENF increased the antiviral potency of a highly active four-drug ARV regimen by 28.5% in ARV-naive, HIV-infected patients. The clinical impact of this finding should be assessed.
References
1.
PalellaF.J.Jr., DelaneyK.M., MoormanA.C.Declining morbidity and mortality among patients with advanced huma immunodeficiency virus infection. HIV Outpatient Study Investigators.N Engl J Med1998; 338: 853–860.
2.
DeeksS.G., HechtF.M., SwansonM.HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy.AIDS1999; 13: F35–F43.
3.
BarlettJ.A., DeMasiR., QuinnJ., MoxhamC., RousseauF.Overview of the effectiveness of triple combination therapy in antirretroviral-naive HIV-1 infected adults.AIDS2001; 15: 1369–1377.
4.
PerelsonA.S., EssungerP., CaoY.Decay characteristics of HIV-1 infected compartments during combination therapy.Nature1997; 387: 188–191.
5.
EasterbrookP.J., NewsonR., IvesN., PereiraS., MoyleG., GazzardB.J.Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens.J AIDS2001; 27: 350–364.
6.
WeverlingG.J., LangeJ., JurriaansS.Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.AIDS1998; 12: F117–F122.
7.
PerelsonA.S., NeumannA.U., MarkowitzM., LeonardJ.M., HoD.D.HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.Science1996; 271: 1582–1586.
8.
PerelsonA.S., NelsonP.W.Mathematical analysis of HIV-I: dynamics in vivo.SIAM Rev1999; 41: 3–44.
9.
MarkowitzM., LouieM., HurleyA.A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo.J Virol2003; 77: 5037–5038.
10.
LouieM., HoganC., Di MascioM.Determining the relative efficacy of highly active antiretroviral therapy.J Infect Dis2003; 187: 896–900.
11.
HoD.D.Dynamics of HIV-1 replication in vivo.J Clin Invest1997; 99: 2565–2567.
12.
LalezariJ.P., HenryK., O'HearnM.Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.N Engl J Med2003; 348: 2175–2185.
13.
LazzarinA., ClotetB., CooperD.Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.N Engl J Med2003; 348: 2186–2195.
14.
ArastèhK., LazzarinA., ClotetB.TORO: 96-week virological and immunological response and safety evaluation of enfuvirtide with an optimized background regimen.15th International AIDS Conference. 11–16 July 2004, Bangkok, Thailand. Abstract MoOrB1058.
15.
Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [monograph on internet]. Rockville: AIDSinfo; 2005 auNNNNK9/7 6[cited 2006 Jan 24]. Available from: http://aidsinfo.nih.gov/content-files/adultandadolescentGL.pdf.
16.
WuH., MellorsJ., RuanP., Mc MahonD., KellerD., & LedermanM.M.Viral dynamics and their relations to baseline factors and longer term virologic responses in treatment-naive HIV-1 infected patients receiving abacavir in combination with HIV-1 protease inhibitors.J AIDS2003; 33: 557–563.
17.
WuH., KuritzkesD.R., McClernonD.R.Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points.J Infect Dis1999; 179: 799–807.
18.
van LethF., HuisamenC.B., BadaroR.Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy.J AIDS2005; 38: 296–300.
19.
PolisM.A., SidorovI.A., YoderC.Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and long-term efficacy.Lancet2001; 358: 1760–1765.
20.
MittlerJ., EssungerP., YuenG.J., ClendeninnN., MarkowitzM., PerelsonA.S.Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy.Antimicrob Agents Chemother2001; 45: 1438–1443.
